Targeted inhibition of Bcl-2 using small molecule inhibitors killed SCLC cell lines treated in vitro and caused regression of established tumors in xenograft models (mice) [82], [83], [84]. This evidence concerns the gene BCL2 and small cell lung carcinoma.